New FDA Approval for Met Exon skipping NSCLC

[LUNGevityKristin]

New Drug Approval Alert: FDA approves capmatinib (Tabrecta) for Met Exon 14 skipping NSCLC – a mutation seen in 3%-4% of #NSCLC. A companion diagnostic to identify these mutations has also been given the green light. The approval reinforces the need for more comprehensive biomarker testing to identify rare mutations and drive better outcomes.

https://www.curetoday.com/articles/fda-approves-tabrecta-the-first-targeted-drug-for-patients-with-nonsmall-cell-lung-cancer-and-met-exon-14?fbclid=IwAR0p68saohJq8-94b4-4HXb4_DCbB-Yio8oRM8yxFX0HZ4BLzS2eSa_viYI